Linden Advisors’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Linden Advisors’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.22K	Hold	337,500	–	–	﹤0.01%	556
2025 Q4	$8.57K	Hold	337,500	–	–	﹤0.01%	464
2025 Q3	$12.2K	Hold	337,500	–	–	﹤0.01%	397
2025 Q2	$14K	Hold	337,500	–	–	﹤0.01%	363
2025 Q1	$23.6K	Hold	337,500	–	–	﹤0.01%	281
2024 Q4	$13.8K	Hold	337,500	–	–	﹤0.01%	244
2024 Q3	$17.1K	Buy	+337,500	New	+$19.5K	﹤0.01%	232

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Linden Advisors's SLXNW Position: Q1 2026 in Review

Linden Advisors held its Silexion Therapeutics Warrant (SLXNW) position steady in Q1 2026 at 337,500 shares worth $7.22K. The position accounts for ﹤0.01% of the portfolio, ranked #556.

Linden Advisors first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $23.6K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

Linden Advisors held 337,500 shares of Silexion Therapeutics Warrant worth $7.22K as of Q1 2026.
Linden Advisors left its Silexion Therapeutics Warrant share count unchanged in Q1 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Linden Advisors's portfolio in Q1 2026, its #556 holding.
Linden Advisors first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Linden Advisors's Silexion Therapeutics Warrant position peaked at $23.6K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Linden Advisors's 13F filing for Q1 2026, filed 15 May 2026.